Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762928 · ClinicalTrials.gov registry record · Phase 1
Estimation OF THE Effect OF Multiple Dose PF-06651600 ON THE Pharmacokinetics OF Single Dose Midazolam AND Efavirenz
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03762928 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT03762928, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The current study will estimate any inhibitive or inductive effect of PF-06651600 on the pharmacokinetics of midazolam and efavirenz.
Interventions
- DRUG midazolam
- DRUG PF-06651600
- DRUG efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762928
The ClinicalTrials.gov registry entry for NCT03762928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which midazolam is the first listed.
NCT03762928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03762928 about?
NCT03762928 is a clinical study titled "Estimation OF THE Effect OF Multiple Dose PF-06651600 ON THE Pharmacokinetics OF Single Dose Midazolam AND Efavirenz". The current study will estimate any inhibitive or inductive effect of PF-06651600 on the pharmacokinetics of midazolam and efavirenz.
What is the current status of trial NCT03762928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-12-07. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT03762928?
The interventions under investigation include: midazolam (DRUG), PF-06651600 (DRUG), efavirenz (DRUG).
Who is sponsoring clinical trial NCT03762928?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.